StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Friday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Price Performance

Shares of TXMD opened at $1.09 on Friday. TherapeuticsMD has a 52 week low of $1.05 and a 52 week high of $2.75. The stock has a 50 day moving average price of $1.38 and a two-hundred day moving average price of $1.62.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP boosted its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.